Samsara Vision

Samsara Vision is a U.S.-based medical device company targeting the high-unmet need of late-stage age-related macular degeneration (AMD), the leading cause of blindness in older Americans. Its core asset is the first and only FDA-approved implantable telescope (IMT) designed to improve central vision. With a commercially approved product in the U.S. and Europe and a next-generation device (SING IMT) in a pivotal U.S. trial, the company is positioned to expand its addressable patient population and improve surgical adoption. Leadership includes seasoned ophthalmology commercial and financial executives from Johnson & Johnson, Alcon, and investment banking.

Implantable miniature telescope technology utilizing micro-optics to project images onto healthy areas of the retina, bypassing central scotomas caused by end-stage retinal diseases like AMD. The platform includes a foldable next-generation design for smaller-incision surgery.

The IMT is first-in-class with no direct competing implantable devices approved for late-stage AMD. Competition primarily comes from low-vision aids (magnifiers, electronic glasses) and visual rehabilitation services. In the broader AMD space, it competes for patient and physician mindshare with anti-VEGF injections (for wet AMD) and newly approved drugs for geographic atrophy. Future competitors may include other visual prosthetics or regenerative therapies.